As the biopharmaceutical sector continues to evolve, a critical focus has emerged around understanding and managing the numerous critical quality attributes (CQAs) that ensure product safety and efficacy. Unlike small molecules, biologics present a far more intricate challenge, boasting potentially millions more CQAs. This complexity necessitates a shift toward innovative monitoring techniques and real-time release strategies, aiming to streamline production processes while maintaining high-quality standards.
The maturation of the biopharmaceutical industry has prompted manufacturers to adopt advanced automation and contemporary methodologies in process design and control. Jose Menezes, CEO of 4Tune Engineering, highlights the stark difference in complexity between biologics and small molecules, with biologics demanding a more nuanced approach to quality management. This reality underscores the industry’s urgent need to identify and prioritize CQAs that are clinically relevant and critical for ensuring patient safety.
In this pursuit, collaborative efforts spearheaded by the BioPhorum Operations Group are underway, focusing on the development of a Biomanufacturing Technology Roadmap. This initiative brings together manufacturers and technology providers to identify best practices for in-line process monitoring and real-time release mechanisms. The group’s ongoing work aims to refine a comprehensive list of priority CQAs, which they plan to share in an upcoming white paper detailing their findings.
A key aspect of this transformation is the push to transition testing from offline methods to real-time assessments conducted directly on the manufacturing floor. Michalle Adkins, director of life sciences consulting at Emerson Process Management, emphasizes the importance of minimizing the complexity of multiple measurements. The goal is to make quality control more efficient and less invasive by reducing the number of connections required during testing.
The working group has identified specific CQAs and in-process controls pertinent to monoclonal antibody (mAb) production, suggesting that their findings could be adapted for other production methods, including continuous and semi-continuous processes. Among the CQAs deemed critical are aggregation and Protein A fragmentation, as well as upstream parameters such as glucose concentration and cell mobility. Downstream, key attributes include turbidity, pH, and conductivity, alongside essential safety measures for virus and microbial control.
Determining the most impactful CQAs involves a thorough analysis of existing testing methodologies, including whether they are performed at-line, offsite, or in-line. This analysis also considers the presence of in-process tests or controls and the strategies employed for release testing and continuous process verification.
The group has made significant headway in developing specifications for user requirements, with initial focus areas including glucose levels, protein aggregation, and amino acid profiles. They are also employing financial assessments, such as return on investment and net present value analyses, to substantiate the business case for implementing these advanced monitoring techniques.
One of the fundamental questions driving this initiative is whether new testing methods are necessary or if current approaches—primarily spectral measurement techniques—can be enhanced. Additionally, the importance of sharing challenge data with suppliers is becoming increasingly evident, as collaboration is crucial to improving overall manufacturing processes.
The viability of in-line testing and real-time release strategies hinges on the unique requirements of each facility, along with a thorough cost-benefit analysis. Early research suggests that full-scale production environments are more likely to support the business case for embracing real-time release, particularly when potential productivity gains can be realized. Adkins posits that these advancements not only stand to improve product yield but also eliminate cumbersome manual sampling processes that are prone to error.
Furthermore, the transition to these modern practices will provide opportunities for workforce upskilling while addressing regulatory concerns, including model validation and change management. The insights gained from this collaborative effort are expected to culminate in a comprehensive white paper set for release later this year, with the working group eager to incorporate further insights from industry stakeholders.
In summary, as the biopharmaceutical landscape becomes increasingly complex, understanding and managing critical quality attributes is paramount. The shift toward real-time monitoring and automated testing will not only enhance quality control but will also pave the way for more efficient and effective manufacturing processes.
Key Takeaways:
- The biopharmaceutical industry faces significant complexity in managing critical quality attributes compared to small molecules.
-
Collaborative initiatives are underway to refine CQAs and improve in-line monitoring and real-time release strategies.
-
Transitioning to real-time testing on the manufacturing floor can streamline quality control and reduce human error.
-
Financial assessments are crucial in establishing the business case for adopting advanced monitoring techniques.
-
Continuous engagement with industry professionals will enrich the development of effective quality management practices.
Read more about it here → pharmtech.com (https://www.pharmtech.com/view/getting-handle-biopharm-s-most-critical-quality-attributes-0)
Tags: automation, quality control, regulatory, upstream, downstream, lyophilization, clinical trials
Read more on pharmtech.com